Pharmacokinetics of high-dose i.v. alizapride in prevention of cisplatin-induced emesis.
Alizapride is a new antidopaminergic-related benzamide with specific antiemetic properties. Pharmacokinetics at a high repetitive dose (16 mg/kg) shows a biexponential plasma decay with T1/2 alpha of 8.33 +/- 2.47 min and T1/2 beta 2.8 +/- 0.7 hr. Large Vdss and high total body clearance are apparent. We demonstrate an increase in drug exposure during the first 6 hr after CDDP infusion by shortening the interval between injections. We conclude that the rate of infusion of alizapride could be important in the efficacy of the drug.
Groupe de Recherches Carcinologiques, Centre Claudius Regaud, Toulouse, France.
P
P
Canal
H
H
Roche
M
M
Pasquier
R
R
Bugat
D
D
Berg
G
G
Soula
M
M
Carton
D000932:Antiemetics / Q000627:therapeutic use*; D002851:Chromatography, High Pressure Liquid; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D011759:Pyrrolidines; C033968:alizapride; D002945:Cisplatin